Exiqon Posts 15 Percent Revenue Increase for Q2 | GenomeWeb

NEW YORK (Genomeweb News) – Exiqon announced today that its second quarter revenues increased 15 percent year over year as it significantly trimmed its net loss for the period.

The Danish firm brought in total revenues of DKK 33.3 million ($5.97 million) for the second quarter, up from DKK 29.1 million for Q2 2012. Exiqon said that its research product sales and services revenue was up 21 percent to DKK 26.8 million from DKK 22.2 million.

The firm cut its net loss to DKK 1.3 million, or DKK .03 per share, from DKK 4.1 million, or DKK .12 per share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.